Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275301 · ClinicalTrials.gov registry record · NA
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT00275301 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 19 participants.
The verdict
NCT00275301, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
Interventions
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275301
The ClinicalTrials.gov registry entry for NCT00275301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which olanzapine is the first listed.
NCT00275301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275301 about?
NCT00275301 is a clinical study titled "PET Imaging and Olanzapine Treatment in Borderline Personality Disorder". The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
What is the current status of trial NCT00275301?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2005-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00275301?
The interventions under investigation include: olanzapine (DRUG).
Who is sponsoring clinical trial NCT00275301?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.